2Hatch GN.Rosuvastatin.Current opinion in cardiovascular, pulmonary and renal investigation[].Drugs.2000 被引量：1
3Graul A,Castaner J.ZD-4522.Hypolipidemic, HMG-CoA reductase inhibitor[].Drugs of the Future.1999 被引量：1
4Olsson A,Pears J,Mckellar J,et al.Effect of rosuvastatin on Low-density lipoprotein cholesterol in patients with hypercholesterolemioa[].The American Journal of Cardiology.2001 被引量：1
5Davidson M,Ma P,Stein E,et al.Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type lla or llb hypercholesterolemia[].The American Journal of Cardiology.2002 被引量：1
6Knopp RH.Drug treatment of lipid disorders[].The New England Journal of Medicine.1999 被引量：1
7Watanabe M,Koike H,Ishiba T,et al.Synthesis and biological activity of methanesulfonamide pyrimidine-and N-methanesulfonyl pyrole-substi tuted 3,5-dihydroxy-6-heptenoates, a novel series of HMGCoA reductase inhibitors[].Bioorganic and Medicinal Chemistry.1997 被引量：1
9Martin PD,Dane AL,Nwose D,et al.No effect of age and gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor[].Journal of Clinical Pharmacology.2002 被引量：1
